NFE2L2 and Friedreich ataxia: The Nrf2-dependent mechanism of action of DMF is particularly intriguing in the context in Friedreich’s ataxia since the only drug recently approved by FDA for the treatment of these patients works by acting on the Nrf2 pathway (Dayalan Naidu and Dinkova-Kostova, 2023).